Radiation dosimetry for 131I-mIBG therapy of neuroblastoma.
This paper describes the methodology which can be used to determine whole-body, red marrow, blood, bladder, liver, and tumour doses delivered during 131I-mIBG therapy of neuroblastoma. The methodology is based on the Physics Protocol used in a multi-centre study undertaken by the United Kingdom Children's Cancer Study Group (UKCCSG). In this study, the estimates of the doses delivered, using 2.4-12.1 GBq 131I-mIBG, were in the following ranges: whole body, 0.14-0.65 mGy MBq-1; red marrow, 0.17-0.63 mGy MBq-1; blood, 0.04-0.17 mGy MBq-1; bladder, 2.2-5.3 mGy MBq-1; liver, 0.3-1.9 mGy MBq-1; and tumour, 0.2-16.6 mGy MBq-1.
Flower
M A
MA
Joint Department of Physics, Royal Marsden NHS Trust, Sutton, Surrey, UK.
Fielding
S L
SL
D019797:3-Iodobenzylguanidine; D002648:Child; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008962:Models, Theoretical; D009447:Neuroblastoma / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D014018:Tissue Distribution
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine